Article thumbnail

Evolution of Extra-Nigral Damage Predicts Behavioural Deficits in a Rat Proteasome Inhibitor Model of Parkinson's Disease

By Anthony C. Vernon, William R. Crum, Saga M. Johansson and Michel Modo


Establishing the neurological basis of behavioural dysfunction is key to provide a better understanding of Parkinson's disease (PD) and facilitate development of effective novel therapies. For this, the relationships between longitudinal structural brain changes associated with motor behaviour were determined in a rat model of PD and validated by post-mortem immunohistochemistry. Rats bearing a nigrostriatal lesion induced by infusion of the proteasome inhibitor lactacystin into the left-medial forebrain bundle and saline-injected controls underwent magnetic resonance imaging (MRI) at baseline (prior to surgery) and 1, 3 and 5 weeks post-surgery with concomitant motor assessments consisting of forelimb grip strength, accelerating rotarod, and apormorphine-induced rotation. Lactacystin-injected rats developed early motor deficits alongside decreased ipsilateral cortical volumes, specifically thinning of the primary motor (M1) and somatosensory cortices and lateral ventricle hypertrophy (as determined by manual segmentation and deformation-based morphometry). Although sustained, motor dysfunction and nigrostriatal damage were maximal by 1 week post-surgery. Additional volume decreases in the ipsilateral ventral midbrain; corpus striatum and thalamus were only evident by week 3 and 5. Whilst cortical MRI volume changes best predicted the degree of motor impairment, post-mortem tyrosine hydroxylase immunoreactivity in the striatum was a better predictor of motor behaviour overall, with the notable exception of performance in the accelerating rotarod, in which, M1 cortical thickness remained the best predictor. These results highlight the importance of identifying extra-nigral regions of damage that impact on behavioural dysfunction from damage to the nigrostriatal system

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson’s disease monitored by magnetic resonance imaging.
  2. (1993). A
  3. (2005). A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson’s disease.
  4. (2010). A deformation-based morphometry study of patients with early-stage Parkinson’s disease.
  5. (2001). A global optimisation method for robust affine registration of brain images.
  6. (2007). A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry.
  7. (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data.
  8. (1997). Alpha-synuclein in Lewy bodies.
  9. (2005). Amygdalar and hippocampal MRI volumetric reductions in Parkinson’s disease with dementia.
  10. (2005). Anisotropic multi-scale fluid registration: evaluation in magnetic resonance breast imaging.
  11. (2006). Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques.
  12. (2009). Asymmetrical lateral ventricular enlargement in Parkinson’s disease.
  13. (1988). Atrophy of medium spiny I striatal dendrites in advanced Parkinson’s disease.
  14. (2002). Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinson’s disease - a functional magnetic resonance imaging study.
  15. (2010). Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson’s disease. Mov Disord.
  16. (2005). Brain atrophy rates in Parkinson’s disease with and without dementia using serial magnetic resonance imaging.
  17. (2006). Brain magnetic resonance study of Mecp2 deletion effects on anatomy and metabolism.
  18. (1971). Central catecholamine turnover and self-stimulation behaviour.
  19. (2005). Cerebral atrophy and its relation to cognitive impairment in Parkinson disease.
  20. (2009). Characterization of proteasome inhibition on astrocytes cell cycle.
  21. (2006). Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures.
  22. (2006). Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats.
  23. (2010). Corticolimbic gray matter loss in Parkinson’s disease without dementia.
  24. (2010). Decreased and increased cortical activation coexist in de novo Parkinson’s disease.
  25. (2000). Degeneration of the centre median-parafascicular complex in Parkinson’s disease.
  26. (2010). Differential progression of brain atrophy in Parkinson’s disease with and without visual hallucinations.
  27. (2009). Diffusion tensor imaging in a rat model of Parkinson’s disease after lesioning of the nigrostriatal tract.
  28. (2008). Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment.
  29. (2010). Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson’s disease.
  30. (2005). Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus.
  31. (2009). Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat–evaluation of time-course and LGR8 expression.
  32. (2008). Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
  33. (2010). fMRI study of motor cortex activity modulation in early Parkinson’s disease.
  34. (2009). Functional brain changes in early Parkinson’s disease during motor response and motor inhibition. Neurobiol Aging.
  35. (2010). Functional changes in the frontal cortex in Parkinson’s disease using a rat model.
  36. (2008). Functional models of Parkinson’s disease: a valuable tool in the development of novel therapies.
  37. (2001). GABA promotes survival but not proliferation of parvalbumin-immunoreactive interneurons in rodent neostriatum: an in vivo study with stereology.
  38. (2008). Generation of a alpha-synuclein-based rat model of Parkinson’s disease.
  39. (2010). Gray matter correlations of cognition in incident Parkinson’s disease.
  40. (2009). Imaging neurodegeneration in Parkinson’s disease.
  41. (2000). Imaging the rat brain on a 1.5 T clinical MR-scanner.
  42. (2002). Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
  43. (2002). Improved optimization for the robust and accurate linear registration and motion correction of brain images.
  44. (2004). Intralaminar thalamic nuclei lesions: widespread impact on dopamine denervation-mediated cellular defects in the rat basal ganglia.
  45. (2009). Lactacystin stimulates stellation of cultured rat cortical astrocytes.
  46. (2008). Longitudinal brain MRI study in a mouse model of Rett Syndrome and the effects of choline.
  47. (2000). Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson’s disease: clinical and therapeutic implications.
  48. (2010). Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature.
  49. (2007). Manganese-enhanced MRI in a rat model of Parkinson’s disease.
  50. (2004). Mapping dopamine function in primates using pharmacologic magnetic resonance imaging.
  51. (2003). Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson’s disease model.
  52. (2000). Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson’s disease.
  53. (2008). Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
  54. (2002). Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
  55. (2010). Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson’s disease discerned with microSPECT and quantitative MRI.
  56. (2010). Neural correlates of bimanual anti-phase and in-phase movements in Parkinson’s disease.
  57. (2010). Neuroanatomical correlates of apathy in Parkinson’s disease: A magnetic resonance imaging study using voxel-based morphometry. Mov Disord.
  58. (2000). Neurological sequelae and long-term behavioural assessment of rats with transient middle cerebral artery occlusion.
  59. (2005). Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration.
  60. (2005). No global loss of neocortical neurons in Parkinson’s disease: a quantitative stereological study.
  61. (2010). Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s disease.
  62. (2007). Noninvasive imaging of neuropathology in a rat model of alpha-synuclein overexpression.
  63. (2009). Parkinson’s disease.
  64. (2008). Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease.
  65. (2007). Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
  66. (2008). Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.
  67. (2002). Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
  68. (2010). Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease.
  69. (2007). Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson’s disease.
  70. (2005). Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson’s disease rat model: a functional MRI study.
  71. (2010). Regional patterns of brain tissue loss associated with depression in Parkinson disease.
  72. (2006). Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.
  73. (2003). Staging of brain pathology related to sporadic Parkinson’s disease.
  74. (2006). Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease.
  75. (1998). Striatal transplantation in a transgenic mouse model of Huntington’s disease.
  76. (2005). Structural brain changes in Parkinson disease with dementia: a voxelbased morphometry study.
  77. (2005). Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.
  78. (2009). Temporal lobe changes in early, untreated Parkinson’s disease.
  79. (2002). Thalamic gray matter changes in unilateral Parkinsonian resting tremor: a voxel-based morphometric analysis of 3-dimensional magnetic resonance imaging.
  80. (2007). The rat brain in stereotaxic co-ordinates.
  81. (2010). Topographical distribution of cerebral cortical thinning in patients with mild Parkinson’s disease without dementia.
  82. (1996). Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods.
  83. (1991). Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator.
  84. (2009). Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington’s disease.
  85. (2002). Volumetric structural magnetic resonance imaging (MRI) of the rat hippocampus following kainic acid (KA) treatment.